These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 16936473

  • 1. Heart rate slowing versus other pharmacological antianginal strategies.
    Diaz A, Tardif JC.
    Adv Cardiol; 2006; 43():65-78. PubMed ID: 16936473
    [Abstract] [Full Text] [Related]

  • 2. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
    Ruzyllo W, Tendera M, Ford I, Fox KM.
    Drugs; 2007; 67(3):393-405. PubMed ID: 17335297
    [Abstract] [Full Text] [Related]

  • 3. Clinical effect of 'pure' heart rate slowing with a prototype If current inhibitor: placebo-controlled experience with ivabradine.
    Borer JS.
    Adv Cardiol; 2006; 43():54-64. PubMed ID: 16936472
    [Abstract] [Full Text] [Related]

  • 4. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S, Timmis AD.
    Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297
    [Abstract] [Full Text] [Related]

  • 5. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 6. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D, Camm JA.
    Drugs; 2004 Jan; 64(16):1757-65. PubMed ID: 15301560
    [Abstract] [Full Text] [Related]

  • 7. Selective and specific I(f) inhibition: new perspectives for the treatment of stable angina.
    Fox K.
    Expert Opin Pharmacother; 2006 Jun; 7(9):1211-20. PubMed ID: 16732707
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.
    Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, INITIATIVE Investigators.
    Eur Heart J; 2005 Dec; 26(23):2529-36. PubMed ID: 16214830
    [Abstract] [Full Text] [Related]

  • 9. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.
    Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators Group.
    Circulation; 2003 Feb 18; 107(6):817-23. PubMed ID: 12591750
    [Abstract] [Full Text] [Related]

  • 10. Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases.
    Tardif JC.
    Drugs Today (Barc); 2008 Mar 18; 44(3):171-81. PubMed ID: 18536779
    [Abstract] [Full Text] [Related]

  • 11. Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction.
    Camici PG, Gloekler S, Levy BI, Skalidis E, Tagliamonte E, Vardas P, Heusch G.
    Int J Cardiol; 2016 Jul 15; 215():1-6. PubMed ID: 27104917
    [Abstract] [Full Text] [Related]

  • 12. Novel If current inhibitor ivabradine: safety considerations.
    Savelieva I, Camm AJ.
    Adv Cardiol; 2006 Jul 15; 43():79-96. PubMed ID: 16936474
    [Abstract] [Full Text] [Related]

  • 13. Ivabradine: new drug. Best avoided in stable angina.
    Prescrire Int; 2007 Apr 15; 16(88):53-6. PubMed ID: 17458043
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Ivabradine in Combination with Beta-Blockers in Patients with Stable Angina Pectoris: A Systematic Review and Meta-analysis.
    Nedoshivin A, Petrova PTS, Karpov Y.
    Adv Ther; 2022 Sep 15; 39(9):4189-4204. PubMed ID: 35842897
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.
    Tardif JC, Ponikowski P, Kahan T, ASSOCIATE Study Investigators.
    Eur Heart J; 2009 Mar 15; 30(5):540-8. PubMed ID: 19136486
    [Abstract] [Full Text] [Related]

  • 16. Focus on ivabradine: a new heart rate-controlling drug.
    Riccioni G.
    Expert Rev Cardiovasc Ther; 2009 Feb 15; 7(2):107-13. PubMed ID: 19210206
    [Abstract] [Full Text] [Related]

  • 17. Future directions: what data do we need?
    Tendera M.
    Adv Cardiol; 2006 Feb 15; 43():106-111. PubMed ID: 16936476
    [Abstract] [Full Text] [Related]

  • 18. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA, Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators.
    JAMA; 2004 Jan 21; 291(3):309-16. PubMed ID: 14734593
    [Abstract] [Full Text] [Related]

  • 19. Cardioprotective effects of the Ιf current inhibition by ivabradine during cardiac dysfunction.
    Su JB.
    Curr Pharm Biotechnol; 2014 Jan 21; 14(14):1213-9. PubMed ID: 24831809
    [Abstract] [Full Text] [Related]

  • 20. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study.
    Müller-Werdan U, Stöckl G, Ebelt H, Nuding S, Höpfner F, Werdan K, ADDITIONS Study Investigators.
    Exp Gerontol; 2014 Nov 21; 59():34-41. PubMed ID: 25193811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.